Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125047993 | 12504799 | 3 | F | 201507 | 20160729 | 20160628 | 20160802 | EXP | PHJP2015JP020578 | NOVARTIS | 71.00 | YR | M | Y | 0.00000 | 20160802 | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125047993 | 12504799 | 1 | PS | TASIGNA | NILOTINIB | 1 | Oral | 300 MG, BID | Y | 22068 | 300 | MG | CAPSULE | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125047993 | 12504799 | 1 | Chronic myeloid leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125047993 | 12504799 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125047993 | 12504799 | Chillblains | |
| 125047993 | 12504799 | Intermittent claudication | |
| 125047993 | 12504799 | Myocardial ischaemia | |
| 125047993 | 12504799 | Pain | |
| 125047993 | 12504799 | Peripheral arterial occlusive disease | |
| 125047993 | 12504799 | Ulcer |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125047993 | 12504799 | 1 | 201505 | 20151117 | 0 |